OrthoPulse is a technology company.
OrthoPulse has raised $5.0M across 1 funding round.
OrthoPulse has raised $5.0M in total across 1 funding round.
I need to clarify an important distinction: OrthoPulse is not a technology company itself—it is a medical device product developed by Biolux Technology, a company that specializes in orthodontic optimization technology.
OrthoPulse is a medical device that uses near-infrared light technology (photobiomodulation) to accelerate orthodontic treatment and reduce associated pain[1][2]. Developed by Biolux Technology, the device is designed for use with both traditional braces and clear aligners, offering patients faster tooth movement, reduced treatment time, and improved comfort[2].
The product addresses a significant pain point in orthodontics: lengthy treatment timelines and patient discomfort. OrthoPulse claims to reduce treatment time by up to 50% through a simple 10-minute daily protocol (5 minutes per arch)[5]. The device has achieved substantial market traction, with doctors worldwide having successfully treated more than 2 million teeth using the technology[2]. The U.S. launch of OrthoPulse 2.0 in July 2024 marked a pivotal expansion, supported by enhanced clinical evidence and new leadership focused on scaling adoption among orthodontic practitioners[1].
OrthoPulse operates at the intersection of digital health, medical devices, and personalized orthodontics. The device represents a shift toward technology-enabled treatment acceleration in a traditionally conservative field. As clear aligners (like Invisalign) have disrupted traditional braces, OrthoPulse addresses the next frontier: reducing treatment duration and improving outcomes through light-based cellular stimulation[1][5].
The timing is significant. Orthodontic patients increasingly demand faster, more comfortable treatment options. By reducing refinements and treatment time, OrthoPulse enhances the economics for orthodontic practices while improving patient satisfaction and compliance[1][4]. The introduction of OrthoPulse Lite signals Biolux's ambition to move from a premium add-on to a standard-of-care technology available to all patients[4].
OrthoPulse is positioned to become a standard tool in modern orthodontic practice. With over 2 million teeth already treated and strong clinical backing, the device has moved beyond early adoption into mainstream adoption among practitioners[2]. The appointment of experienced leadership (Michael Hendricks as Chief Business Officer North America) and the launch of OrthoPulse Lite suggest Biolux is focused on scaling market penetration and establishing the technology as essential rather than optional[1][4].
The company's future likely hinges on three factors: continued clinical evidence generation, expansion of the practitioner network in North America and internationally, and successful market positioning of OrthoPulse Lite as an accessible, high-value tool. If adoption accelerates, OrthoPulse could reshape treatment timelines across the orthodontic industry, creating a new standard where accelerated treatment becomes the norm rather than a premium service.
OrthoPulse has raised $5.0M in total across 1 funding round.
OrthoPulse's investors include LifeX Ventures, Redalpine Venture Partners.
OrthoPulse has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $5.0M Seed | LifeX Ventures, Redalpine Venture Partners |